Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma ; volume:23 ; number:1 ; day:29 ; month:8 ; year:2023 ; pages:1-10 ; date:12.2023
BMC cancer ; 23, Heft 1 (29.8.2023), 1-10, 12.2023
- Creator
-
Chen, Yen-Hao
Tsai, Ching-Hua
Chen, Yen-Yang
Wang, Chih-Chi
Wang, Jing-Houng
Hung, Chao-Hung
Kuo, Yuan-Hung
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-023-11298-z
- URN
-
urn:nbn:de:101:1-2023110711534685421776
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chen, Yen-Hao
- Tsai, Ching-Hua
- Chen, Yen-Yang
- Wang, Chih-Chi
- Wang, Jing-Houng
- Hung, Chao-Hung
- Kuo, Yuan-Hung
- SpringerLink (Online service)
Other Objects (12)
Low-dose nivolumab in advanced hepatocellular carcinoma
Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study
Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study
Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma
Metastatic Melanoma Treatment with Pembrolizumab after Hypersensitivity Reaction to Nivolumab: A Case Report
Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients
Low-dose nivolumab in advanced hepatocellular carcinoma
Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study
Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study
Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma
Metastatic Melanoma Treatment with Pembrolizumab after Hypersensitivity Reaction to Nivolumab: A Case Report
Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients
Low-dose nivolumab in advanced hepatocellular carcinoma
Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study
Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study
Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma
Metastatic Melanoma Treatment with Pembrolizumab after Hypersensitivity Reaction to Nivolumab: A Case Report